Journals / Bakırköy Tıp Dergisi / 2019 / Cilt: 15 - Sayı: 2

Evaluation of Serum Lipid Parameters in Acromegaly Patients

Akromegali Hastalarda Serum Lipit Parametrelerinin Değerlendirilmesi

Pages
150–154
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies seem necessary for more clarifica-tion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In acromegaly, the incidence of cardiovascular disease is higher compared to healthy population because of the association of secondary cardiovascular disease risk factors such as hypertension, glucose intolerance, dyslipidemia, and insulin resistance.
📊
Key Findings & Data:This study aimed to evaluate the relationship between Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), and lipid profiles in patients with newly diagnosed acromegaly.
💡
Conclusion & Impact:Further studies seem necessary for more clarifica-tion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In acromegaly, the incidence of cardiovascular disease is higher compared to healthy population because of the association of secondary cardiovascular disease risk factors such as hypertension, glucose intolerance, dyslipidemia, and insulin resistance. This study aimed to evaluate the relationship between Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), and lipid profiles in patients with newly diagnosed acromegaly. Methods: This study included 57 newly diagnosed acromegaly patients and 31 healthy control cases. Blood samples were taken after a 12-hour night fasting to analyze the levels of the hormones, the lipid profiles, and the fasting blood glucose. Results: The mean of LDL-C level in the acromegaly group and control group were respectively 140.2±61.3 mg/dL and 115.6±30.4 mg/dL, (p=0.029), triglyceride level 137.6±84.0 mg/dL and 102.9±43.0 mg/dL, (p=0.027) and HDL-C level 41.5±10.5 mg/dL and 50.5±10.6 mg/dL, (p=0.001). There was a significant positive correlation between GH levels of LDL (r=0.375, p=0.002), TG (r=0.302, p=0.01), IGF-1 (r=0.634, p=0.0001) and HOMA-IR (r=0.699, p=0.0001), IGF-1 and LDL levels (r=0.295, p=0.01) and TG (r=0.476, p=0.0001). There was a negative correlation between HDL and GH (r=-0.399, p=0.001) and HDL with IGF-1 (r=-0.310, p=0.01). Conclusions: Acromegaly is a disorder characterized by an excess of GH and GH appears to adversely affect the lipid profile. It can be considered that this risk factor may be eliminated by the control of the levels of GH and IGF-1 in acromegaly patients. Further studies seem necessary for more clarifica-tion.

Özet

Amaç: Akromegalide, hipertansiyon, glukoz intoleransı, dislipidemi ve insülin direnci gibi sekonder kardiyovasküler hastalık risk faktörleri arasındaki ilişki nedeniyle, normal topluma kıyasla kardiyovasküler hastalık insidansı artmıştır. Bu çalışmada yeni tanı almış akromegali hastalarında Growth Hormon (GH), insulin benzeri büyüme faktörü-1 (IGF-1) ve lipit profilleri arasındaki ilişkinin incelenmesi amaçlandı. Yöntemler: Bu çalışmaya yeni tanı almış 57 akromegali hastası ve sağlıklı kontrol grubu olarak da 31 kişi dahil edildi. On iki saat bir gecelik açlıktan sonra hormonlar, açlık kan şekeri ve lipid düzeyleri için kan alındı. Bulgular: Akromegali ve kontrol grubunda sırasıyla; Düşük dansiteli lipoprotein (LDL) kolesterol düzeyi 140,2±61,3 mg/dL ve 115,6±30,4 mg/dL (p=0,029), TG düzeyi 137,6±84,0 mg/dL ve 102,9±43,0 mg/dL (p=0,027) ve Yüksek dansiteli lipoprotein (HDL) kolesterol düzeyi 41,5±10,5 mg/dL ve 50,5±10,6 mg/dL (p=0,001) bulundu. GH düzeyi ile LDL (r=0,375, p=0,002), TG (r=0,302, p=0,01), IGF-1 (r=0,634, p=0,0001) ve HOMA-IR arasında (r=0,699, p=0,0001), IGF-1 düzeyi ile LDL (r=0,295, p=0,01) ve TG (r=0,476, p=0,0001) arasında anlamlı pozitif korelasyon tespit edildi. GH ile HDL (r=-0,399, p=0,001) ve IGF-1 ile HDL arasında (r=-0,310, p=0,01) anlamlı negatif korelasyon tespit edildi Sonuç: Akromegali GH fazlalığı ile seyreden bir hastalıktır ve GH’nin lipid profilini kötü yönde etkilediği görülmektedir. Akromegali hastalarında GH ve IGF-1 düzeylerinin kontrolü ile bu risk faktörünün elimine edilebileceği düşünülebilir. Daha fazla açıklama için daha ileri çalışmalara ihtiyaç vardır.

🔖

Cite This Article

KESKİN, H., ÇADIRCI, K., KAYA, Y., DURMAZ, Ş., ARSLAN, A., YILDIZ, F., GÖZCÜ, H., Budak, M. E., ÇARLIOĞLU, A. (2019). Evaluation of Serum Lipid Parameters in Acromegaly Patients. Bakırköy Tıp Dergisi, Cilt: 15 - Sayı: 2, 150–154. https://ajindex.com/articles/125465

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary 2015;18:803-7.
  2. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary 2017;20:4-9.
  3. Lopez-Velasco R, Escobar-Morreale HF, Vega B, Vılla E, Sancho JM, Moya-Mur JL, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997;82:1047-53. Mearns BM. Targeting levels and functions of blood lipids in the prevention of CVD. Nat Rev Cardiol 2011;8:179-80. CVD Statistics - European Heart Network. European Cardiovascular Disease Statistics 2017 [online]. Available from URL: http://www. ehnheart.org/cvd-statistics/cvd-statistics-2017.html Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009;94:523-7.
  4. Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 2004;61:138-44.
  5. Carroll PV, Jenkins PJ. Acromegaly. Editors In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext (Internet). South Dartmouth (MA): MD Text.com, Inc; 2000-2012 Mar 26 Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC, et al. Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab 2015;100:2946-55.
  6. Işıldak M, Güven GS, Gürlek A. Metabolik sendrom ve insulin direnci. Haccettepe Tıp Dergisi 2004;35:96-9.
  7. Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 2007;13:363-72.
  8. Boero L, Manavela M, Merono T, Maidana P, Gomez Rosso L, Brites F. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin Endocrinol (Oxf) 2012;77:579-85.
  9. Boero L, Cuniberti L, Magnani N, Manavela M, Yapur V, Bustos M, et al. Increased oxidized low density lipoprotein associated with